The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

What is the correlation between Nottingham score and receptor status in malignant breast cancer

Print

Sub-category:
Proteomics/Immunohistochemistry

Category:
All

Meeting:
2008 Molecular Markers

Session Type and Session Title:
General Poster Session B

Abstract No:
86

Author(s):
M. Mokri, M. Guity, S. Shariat Torbaghan, M. Bagherzadeh, M. Atri

Abstract:

Background: The Nottingham score (NS), a histological grading system for invasive breast carcinoma include by; Tubule formation, Nuclear pleomorphism and Mitotic rate as criteria and each are assigned 1,2 or 3 points and the scores are added for a combined histological score. Tumors are graded based on the combined score into grade I (3-5, well differentiated), grade II (6-7, moderately differentiated) and grade III (8-9 poorly differentiated). Hormones receptors (ER and PR) and Her-2/neu gene or its protein are now routinely evaluated in all breast cancer cases. Her- 2/neu overexpression is associated with features of a poor prognosis like high tumor grade and S- phase fraction, nodal metastasis and estrogen (ER) and progesterone receptor (PR) negativity. Its overexpression produces ligand independent down regulation of ER. The reduced hormone receptor expression might be one of the mechanism by which HER2/neu positive tumors show a decreased response to hormonal agents and decreased DFS. Methods: The data on all women reviewed pathology reports invasive ductal carcinoma of breast cancer in our community hospital were retrospectively analyzed. The final analysis had 420 patients. The receptor status and NS were tabulated. We divided all the patients into Her-2/neupositive 185 and negative 235 and later subdivided into hormone receptor (both ER and PR) negative or positive (ER or PR). Results: Her2/neu neg, ER or PR (+ ) in NS 3-5, NS 6-7 and NS 8-9 arrangement by: 3 (5.5%), 11 (40.3%) and 10 (34.4%). Her2/neu neg, ER and PR (- )in NS 3-5, NS 6-7 and NS 8-9 arrangement by: 7 (4.9%), 17 (11.9%) and 30 (21%). Her2/neu pos, ER or PR (+) in NS 3-5, NS 6-7 and NS 8-9 arrangement by: 4 (8.2%), 6 (26.9%) and 9 (47.6%). Her2/neupos, ER and PR (-) in NS 3-5, NS 6-7 and NS 8-9 arrangement by: 5 (3.1%), 15 (9.4%) and 37 (23.1%). Conclusions: In this study itis observed that ER or PR positivity shows a trend towards lower NS. The patents with triple receptor negative status had higher NS. This suggests a correlation between NS, receptor status and DFS.


Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


  Associated Presentation(s):

    

1. What is the correlation between Nottingham score and receptor status in malignant breast cancer

Meeting: 2008 Molecular Markers
Presenter: Mehrdad Mokri, MD
Session: General Poster Session B (General Poster Session)


  Other Abstracts in this Sub-Category:

    

1. Relationship of expression of S100A2 calcium-binding protein and response to pancreatectomy for pancreatic cancer

Meeting: 2008 Molecular Markers   Abstract No: 59   First Author: A. V. Biankin
Category: All - Proteomics/Immunohistochemistry

    

2. Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multi-institutional study

Meeting: 2008 Molecular Markers   Abstract No: 60   First Author: J. A. Karam
Category: All - Proteomics/Immunohistochemistry

    

3. Multi-institutional external validation of the predictive value of KI-67 labeling index in patients treated with radical cystectomy

Meeting: 2008 Molecular Markers   Abstract No: 61   First Author: S. Shariat
Category: All - Proteomics/Immunohistochemistry

    

More...


  Abstracts by M. Mokri:

    

1. What is the correlation between Nottingham score and receptor status in malignant breast cancer

Meeting: 2008 Molecular Markers   Abstract No: 86   First Author: M. Mokri
Category: All - Proteomics/Immunohistochemistry

    

2. Current demographics and outcomes of resectable breast cancer in Iranian women

Meeting: 2008 Breast Cancer Symposium   Abstract No: 108   First Author: M. Mokri
Category: Epidemiology, Biology, and Health Services Research - Other: Epidemiology, Biology, and Health Services Research

    

3. Factors affecting disease free survival in Iranian patients with invasive ductal carcinoma of the breast.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 22130   First Author: M. Mokri
Category: Tumor Biology and Human Genetics - Prognostic Factors

    

More...


  Presentations by M. Mokri:

    

1. What is the correlation between Nottingham score and receptor status in malignant breast cancer

Meeting: 2008 Molecular Markers
Presenter: Mehrdad Mokri, MD
Session: General Poster Session B (General Poster Session)

    

2. Current demographics and outcomes of resectable breast cancer in Iranian women

Meeting: 2008 Breast Cancer Symposium
Presenter: Mehrdad Mokri, MD
Session: General Poster Session A (General Poster Session)

    

3. Introducing a scoring system based on Her2/neu, p53 and mammography results for correlation of Nottingham score in invasive ductal carcinoma.

Meeting: 2007 Breast Cancer Symposium
Presenter: Mehrdad Mokri
Session: General Poster Session A (General Poster Session)

    

More...


  Educational Book Manuscripts by M. Mokri:

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.